Medicine and Dentistry
Patient
100%
Breast Cancer
53%
Inpatient
38%
Chemotherapy
29%
Overall Survival
25%
Metastatic Breast Cancer
22%
Neoplasm
19%
Surgery
17%
Neoadjuvant Chemotherapy
16%
Survival
15%
Gamma Urogastrone
13%
Malignant Neoplasm
12%
Progression Free Survival
12%
Analysis
12%
Hormone Receptor
11%
Triple Negative Breast Cancer
11%
Epidermal Growth Factor Receptor 2
11%
Combination Therapy
9%
Recurrent Disease
8%
Prognostic Factor
8%
Hazard Ratio
7%
Fluorouracil
7%
Trastuzumab
7%
Age
7%
Disease Free Survival
7%
Paclitaxel
7%
Association
6%
Chemoradiotherapy
6%
Disease
6%
Toxicity
6%
Woman
6%
Epidermal Growth Factor Receptor
6%
Follow up
6%
Breast
6%
Olaparib
6%
Placebo
5%
Hormone Therapy
5%
Metastatic Carcinoma
5%
Bile Duct Cancer
5%
Radiation Therapy
5%
Multivariate Analysis
5%
Gemcitabine
5%
Survival Rate
5%
Docetaxel
5%
Non Small Cell Lung Cancer
5%
Recurrence Free Survival
5%
Biological Marker
5%
Fulvestrant
5%
Colorectal Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
48%
Chemotherapy
34%
Metastatic Breast Cancer
25%
Overall Survival
24%
Stomach Cancer
20%
Gamma Urogastrone
18%
Progression Free Survival
16%
Trastuzumab
15%
Epidermal Growth Factor Receptor 2
15%
Neoplasm
14%
Hormone Receptor
13%
Survival
13%
Toxicity
10%
Malignant Neoplasm
10%
Fluorouracil
10%
Paclitaxel
10%
Diseases
9%
Palbociclib
9%
Fulvestrant
7%
Adverse Event
7%
Epidermal Growth Factor Receptor
7%
Recurrent Disease
7%
Capecitabine
7%
Cisplatin
6%
Taxane
6%
Triple Negative Breast Cancer
6%
Gemcitabine
6%
Docetaxel
6%
Disease Free Survival
6%
Pertuzumab
5%
Oxaliplatin
5%
Neutropenia
5%
Blindness
5%
Survival Rate
5%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
11%
Epidermal Growth Factor Receptor
9%
Overall Survival
8%
Survival
6%
Mutation
6%
Progression Free Survival
5%